OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD

OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD
OSE Immunotherapeutics presented new preclinical results on its investigational therapy candidate OSE-127, further validating its potential for the treatment of inflammatory bowel diseases (IBD). Results were presented in an abstract titled, “Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα therapy in IBD,” at the recent 
Subscribe or to access all post and page content.